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Abstract 
 
 
Current findings continue to support the concept of a biologically defective decidua 
rather than a primarily abnormally invasive trophoblast. Prior caesarean sections 
increase the risk of placenta praevia and both adherent and invasive placenta accreta, 
suggesting that the endometrial/decidual defect following the iatrogenic creation of a 
uterine myometrium scar has an adverse effect on early implantation. Preferential 
attachment of the blastocyst to scar tissue facilitates abnormally deep invasion of 
trophoblastic cells and interactions with the radial and arcuate arteries. Subsequent high 
velocity maternal arterial inflow into the placenta creates large lacunae, destroying the 
normal cotyledonary arrangement of the villi. 
 
Key Words: Placenta accreta; placenta increta; placenta percreta; ultrasound 
diagnosis; histopathology. 
 
 
 
Definitions 
 Placenta accreta: general term used to describe the different levels or grades of 
the accrete placenta spectrum. 
 Placenta creta: histologic description of placental villi adherent to the 
myometrium without interposing decidua. 
 Placenta increta: clinical description of placenta villi invading the myometrium 
down to the uterine serosa. 
 Placenta percreta: clinical description of placenta villi invading the entire uterine 
wall and beyond. 
 Morbidly adherent placenta: 19th Century clinical terminology used to describe 
placenta retention due to various causes including placenta creta.  
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Introduction 
To understand the pathophysiology of accreta placentation it is essential to look into the 
history of its epidemiology. The first case reports of placenta accreta (PA) were 
published in the literature in the 1920s, and the first series in 1937 by the obstetrician 
Frederick C. Irving and the pathologist Arthur T. Hertig from the Boston Lying-In 
Hospital [1]. In 1927, Dr DS Forster, a scholar in gynaecology at the Pathology 
Department of the Montreal General Hospital, Montreal, Canada described a case of PA 
with invasive villi following a prior caesarean delivery (CD) [2]. This was the only case in 
8,000 deliveries during a 6-year period at the Montreal maternity hospital, indicating the 
rarity of the condition at that time. Modern caesarean sections were introduced in 
obstetric practice at the end of the 19th century, but were seldom performed until the 
1920s [3]. Not surprisingly, only one of the 20 cases of PA personally treated by Irving 
and Hertig occurred after a previous CD [1]. Similarly, in their review of 86 case reports 
up to 1935, only one was found after a prior CD. They concluded that the predisposing 
factors of PA at the time were a previous manual delivery and/or “vigorous” uterine 
curettage. They calculated the prevalence of accreta placentation in their population to 
be around 1 in 1,956 deliveries. The paper by Irving and Hertig was published in a 
journal that no longer exists and thus is not recorded in PubMed. There are no other 
publications on placenta accreta between 1927 and 1944. 
 Major technical advances in surgical and anaesthetic techniques and the advent 
of antibiotics and blood transfusions in the 1940s substantially reduced the morbidity 
and mortality of CD [3]. As a consequence, increasingly women not only survive the 
procedure but also are able to have one or more subsequent pregnancies. Before the 
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advent of ultrasound and magnetic resonance imaging (MRI), the diagnosis of PA was 
exclusively clinical and made at birth. In the 1920s, PA was diagnosed “when the 
placenta fails to be delivered, following the birth of the child” [2]. Irving and Hertig 
defined PA as the abnormal adherence either in whole or in part of “the afterbirth” to the 
underlying uterine wall [1]. Their study became a “classic” but none of their cases had 
villous tissue invading the myometrium. This fact has led to a lot of confusion for 
obstetricians struggling with the delivery of a “sticky” placenta. Indeed, the clinical 
definition of a superficially adherent PA is very similar to that of placental retention and 
has not changed since the 1930s.  
Like for all other life-threatening pathologies in obstetrics and gynaecology, 
histopathologic examination remains the gold diagnostic standard to evaluate 
epidemiologic trends and calculate health care provision. It is essential to confirm the 
depth of villous invasion of the uterine myometrium in order to improve clinical 
management. Histopathologic examination also permits immunohistochemical (IHC) 
and molecular biological studies of the underlying mechanisms leading to abnormal 
adherence or invasive placentation. We present here a review the recent findings on the 
pathophysiology of PA. To facilitate the discussion, we use the term placenta accreta 
spectrum (PAS) to include both adherent and invasive placental disorders. 
 
BACKGROUND EPIDEMIOLOGY 
By 1966, when Luke et al, published their series of PAS, nine of their 21 cases had a 
previous history of CD [4]. All recent epidemiologic studies have shown a clear 
association between the CD rate and the incidence of accreta placentation in 
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subsequent pregnancies [5-8]. There has been an exponential increase in global rates 
of CD, which was particularly marked over the past 25 years with rates increasing from 
less than 7% in 1990 to over 19% in 2014 [9]. Currently, the highest regional CD rates 
are found in Latin America (40-50%) and the lowest in sub-Saharan Africa (3-6%). In 
Europe, the CD rates vary from 22% in the North to 31% in the South, whereas in 
Northern America the CD rate is now 32.3%. Countries such as Egypt, Turkey, Brazil 
have national CD rates over 55% and rising [10]. The incidence of PAS increases with 
the number of prior CDs [5-8], and a previous caesarean section has been the main 
cause of PAS for the last two decades [8]. Changes in the prevalence of PAS 
secondary to changes in CD rates are often delayed by one or two decades [8] 
depending on local birth rates. Thus, countries with both a high birth rate and a very 
high CD rate and rising, such as Egypt, will soon have the highest maternal morbidity 
and mortality due to PAS. 
 For an unknown reason, placenta accreta including its invasive forms increta and 
percreta, has increasingly been referred to as “morbidly adherent” placenta or MAP 
which is a 19th century terminology used to describe placental retention after delivery. 
Many modern authors still use the old clinical criteria to define an accreta placenta i.e. 
difficult manual, piecemeal removal of the placenta, absence of spontaneous placental 
separation 20-30 min after birth despite active management including bimanual 
massage of the uterus, use of oxytocin and controlled traction of the umbilical cord, 
retained placental fragment requiring curettage after vaginal birth and heavy bleeding 
from the placentation site after removal of the placenta during CD [11,12].  
 Since the 1920s, the primary method of management has been emergency 
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hysterectomy, with the diagnosis being confirmed by histopathologic examination in 
most case reports and series. Although the vast majority of PAS cases diagnosed 
prenatally or at delivery are still managed by hysterectomy, more than half of the 
authors do not provide detailed data on histopathologic confirmation of the diagnosis of 
placenta accreta and even more very rarely on the differential diagnosis between 
adherent and invasive accreta [13,14]. Thus, many cohort studies on the diagnosis and 
management of PAS include a mixed bag of cases with various degrees of invasion of 
the myometrium by chorionic villi. The MAP terminology excludes the more invasive 
forms of accreta placentation, and adds to the confusion in the clinical differential 
diagnosis at delivery between PAS and placental retention [14]. This lack of precise 
diagnosis can explain the wide variation in incidence and prevalence of PAS reported in 
the international literature in the last two decades [8].  
 The single other most important risk factor, reported in around 50% of all cases 
of PAS disorders, is placenta previa. The risk of previa also increases with the number 
of prior CDs [8]. Women with a prior history of CD, presenting with a low-lying placenta 
or placenta previa, now represent the group with the highest risk of PAS [13]. This 
epidemiologic association also indicates that a previous uterine scar can have an 
impact on both implantation and placentation.  
 
ACCRETA PLACENTATION 
Irving and Hertig were the first to suggest that the pathological basis of PAS is the 
complete or partial absence of the decidua basalis [1]. Since then, several concepts 
have been proposed to explain why and how PA occurs [10,15]. The oldest concept is 
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 7 
based on a theoretical primary defect of trophoblast biology leading to excessive 
attachment or invasion of the myometrium. The current hypothesis is that of a 
secondary defect of the endometrial-myometrial interface leading to a failure of normal 
decidualisation in the area of the uterine scar allowing abnormally deep placentation. An 
abnormal vascularisation resulting from the scaring process after surgery, with 
secondary localized hypoxia leading to both defective decidualization and excessive 
trophoblastic invasion, has also been suggested [16]. 
 
Development of the uterine scar 
Major surgical procedures such as caesarean sections or myomectomies that cut 
through the entire uterine wall will leave a scar through all the smooth muscular layers 
of the myometrium. Unlike the epithelial layers of the endometrium and uterine 
peritoneum that heal by regeneration and recolonization of scar area, the myometrium, 
does not heal by regenerating muscle fibers, but by forming “foreign” substances 
including collagen [15]. Myofibre disarray, tissue edema, inflammation and elastosis 
have all been observed in uterine wound healing after surgery. The resulting scar tissue 
is less elastic and more prone to injury/rupture in subsequent pregnancies than the 
intact muscle. Different surgical techniques such as single-layer versus double-layer 
closure of the myometrium, locked versus unlocked single-layer closure [8] or the suture 
material used for the closure may have an influence on the healing process and the 
risks of uterine rupture, but the evidence regarding the risk of PAS in subsequent 
pregnancies remains limited. 
Compared with women with a primary CD, women who undergo a repeat 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 8 
cesarean are more than twice as likely to have PAS disorders [8]. Multiple CD (MCD) 
scars are often associated with a clear loss of myometrium or a defect (Fig. 1A) with a 
direct communication between the endometrial cavity and the visceral serosa [15]. 
Residual myometrial thickness is greater and scar defect length, but not depth and 
width, is shorter following double-layer compared with single-layer closure. Large 
caesarean scar defects (CSD) may lead to scar dehiscence with advancing gestation 
(Fig 1.B), and could even explain rare reports of placenta percreta leading to uterine 
rupture in the first half of pregnancy. Although this is an extremely rare complication of 
placentation, the mechanism of uterine rupture due to a placenta percreta is likely to be 
similar to that of a tubal rupture in an ectopic placentation. The strong epidemiologic 
association between placenta previa and PAS findings suggest that the decidual defect 
following the artificial creation of a scar in the uterine myometrium has an adverse effect 
on both early implantation by creating conditions for preferential attachment of the 
blastocyst to scar tissue and facilitating abnormally deep placental invasion.  
Leukocyte recruitment to the endometrium is observed during the normal 
secretory phase, and has been reported to be increased following a CD [10,15]. A prior 
CD increases not only the risk of PAS in subsequent pregnancies but also the risk of 
placenta praevia [8], suggesting a tropism of the blastocyst for the scar area. The 
uterine artery resistance is increased, and the volume of uterine blood flow as a fraction 
of maternal cardiac output is decreased in women with a previous CD compared to 
women with a previous vaginal birth [17]. Overall, these data suggest a possible 
relationship between a poorly vascularized uterine scar area and an increase in the 
resistance to blood flow in the uterine circulation. A large scar area resulting from MCD 
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 9 
and scar dehiscence is likely to have an impact on endometrial re-epithelialisation. 
Decidualization may be sparse or absent in the overlying area and the absence of 
structured myometrium underneath is more likely to lead to invasive (increta or percreta) 
PAS. 
PAS is not exclusively a consequence of caesarean scar and any form of 
damage, even small, to the integrity of the uterine lining following curettage, 
myomectomy, or endometrial resection has been associated with PAS in subsequent 
pregnancies [8,10]. Uterine anomalies, adenomyosis and submucous fibroids have also 
been associated with PAS in primigest women [8]. Endometritis can lead to endometrial 
fibrosis and poor decidualization and thus to development of PAS. This can explain why 
before the advent of antibiotics a prior manual removal of the placenta with or without a 
uterine curettage was the main factor associated with PAS in subsequent pregnancies 
[1]. The trauma to the myometrium and the surface of the endometrium is often limited 
in a curettage procedure, and should not be associated with the absence of re-
epithelialization of the scar area and changes in the surrounding uterine circulation 
compared with the larger and deeper scars resulting from MCD. If the myometrium scar 
is small, the placenta may simply grow over it, which can explain why more than 90% of 
cases of placenta praevia in women with one prior CD are not accreta [10]. Within this 
context, if PAS develops it is more likely to be superficial (adherent) and focal. 
 
Characteristics of the accreta trophoblast 
There are two types of trophoblast: the villous trophoblast which covers the placental 
villi and which is made up of cytotrophoblast cells and the syncytiotrophoblast, and the 
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extravillous trophoblast (EVT) which arises from the distal tips of the anchoring villi that 
normally make contact with the decidua basalis. The EVT differentiate primarily into 
interstitial and endovascular cells sub-populations that migrate through the decidual 
stroma and down the lumens of the spiral arteries respectively. The interstitial EVT 
invade the uterine wall as far as the inner third of the uterine myometrium, also called 
the junctional-zone (JZ), where they fuse to form multinucleated trophoblast giant cells 
(MNGCs) [10,18]. In the weeks following implantation, EVT cells are found both within 
and around the spiral arteries in the central area of the placenta. EVT gradually migrate 
laterally, reaching the periphery of the placenta around mid-gestation. Endovascular 
EVT cells in the central area, destined to become the definitive placenta, act as plugs 
blocking the spiral arteries. These plugs prevent a continuous flow of maternal blood 
from entering the placenta during most of the first trimester [18]. This phenomenon 
creates an environment of physiological hypoxia inside the gestational sac, which is 
essential for normal fetal-placental development and which modulates the formation of 
the membranes of definitive placenta.  
Both endovascular and interstitial EVT invasion are associated with the 
physiological conversion of the terminal part of the uterine circulation, extending as far 
the basal part of the spiral arteries at the level of the JZ or the inner third of the 
myometrium [10]. Around 30-50 spiral arteries are transformed during the first trimester. 
In normal pregnancies, the transformation of spiral arteries into utero-placental arteries 
is described as complete around mid-gestation. There is a gradient in the infiltration of 
the EVT along the spiral artery, and even in a normal pregnancy not all spiral arteries 
are completely transformed [18]. In humans, it is obvious that the decidua does not act 
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as a barrier but rather as a matrix that allows the EVT cells to colonise the JZ in a 
regulated manner. Trophoblast invasion is notably more aggressive and more 
penetrative at sites of ectopic implantation, for example in the Fallopian tube, in the 
absence of decidua. As EVT cells differentiate, they progressively display a more 
migratory phenotype, changing their integrin repertoire from predominantly collagen IV 
receptors to fibronectin and then laminin receptors [10,15]. An array of factors operates 
upstream of these pathways to stimulate trophoblast invasion and includes; cytokines 
and growth factors, such as epidermal growth factor, vascular endothelial growth factor 
(VEGF), interleukin-1ß, tumour necrosis factor-α and the hyperglycoslyated form of 
hCG; hormones, such as triiodothyronine, leptin and gonadotropin-releasing hormone-1; 
and low (1%) oxygen concentrations [15,18]. Equally important in the regulation of 
placentation are the inhibitors of trophoblast invasion. The precise regulation of 
trophoblast invasion will therefore depend on the balance of local concentrations of 
many factors, and also the composition of the extracellular matrix.  
We have recently reviewed the main findings from histopathologic studies in PAS 
[15,18], which are displayed in Table 1. There are wide variations in study design, 
accreta definition, number of cases studied, type of tissue investigated and the extent of 
quantification of morphological changes. In brief, the villous tissue shows no 
morphological changes in PAS compared to non-accreta placentas, even in the invasive 
areas (Fig. 2). The syncytiotrophoblast in PAS villous tissue shows reduced 
immunostaining for MicroRNA-34a, E-cadherin (E-CAD), epidermal growth factor EGF 
c-(erbB-2), transforming growth factor beta (TGF-β), vascular endothelial growth factor 
receptor 2 (VEGFR-2) and endothelial cell receptor tyrosine kinase (RTK) Tie-2. By 
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contrast, there is increased syncytiotrophoblast labelling for epidermal growth factor 
receptor (EGFR) and TIMP-1 tissue inhibitors of matrix metalloproteinase (TIMP-1) in 
PAS. These data suggest that abnormal villous adherence develops as a result of 
abnormal expression of growth-, angiogenesis- and invasion-related factors in the 
different trophoblast populations. Lower expression of MicroRNA-34a may indicate a 
dysregulation of the trophoblastic cellular invasive capacity. However, the villous 
syncytiotrophoblast has no invasive capacity and there is no evidence that these 
biological changes have any impact on overall feto-placental development. Thus, these 
data are difficult to interpret and could be secondary to a focal environmental change in 
utero-placental blood flow, in particular in the oxygen concentration changes within the 
intervillous space in the invasive areas. 
EVT cells in PAS are increased in size and number, as well as in the depth of 
myometrial invasion. However, they form fewer MNGCs, indicating that they have not 
undergone their normal terminal differentiation. Immunohistochemistry has shown 
increased vascular endothelial growth factor (VEGF) and phosphotyrosine in EVT cells 
from PAS cases compared to normal controls [16]. EVT cells lose their invasive 
phenotype through syncytial-type fusion into MNGCs, and the secretion of VEGF by 
MNGCs is likely to be one of the signals initiating and coordinating vascularization in the 
decidua and placenta during implantation. Lower immunostaining for soluble fms-like 
tyrosine kinase (sFLT-1), which is a potent antiangiogenic growth factor, has been 
observed in the EVT cells of women presenting with PA. These findings suggest that 
VEGF and sFLT-1 play pivotal roles in the process of pathological programming of 
EVTs toward increased motility and invasiveness in PAS.  
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Placenta increta and percreta are not due to a further invasion of EVT in the 
uterine wall. They are likely to arise secondary to the dehiscence of a scar, leading to 
the presence of anchoring villi deep within the uterine wall, and thus giving EVTs 
greater access to the deep myometrium and beyond. Overall, these results suggest that 
accreta placentation does not arise through excessive EVT invasiveness or proliferation 
and that the absence of the JZ is of more importance in the pathogenesis. The 
comparison of ultrasound features of uterine caesarean scar with histological findings 
has shown that large and deep myometrial defects are often associated with absence of 
re-epithelialisation of the scar area [10,15]. These findings also emphasise the role of 
the sub-decidual myometrium of the JZ in modulating placentation. The absence of 
decidua in first-trimester cases of PA negates previous suggestions that decidua is 
normal at the beginning of gestation and atrophies as pregnancy proceeds [15].  
 
Characteristics of utero-placental vasculature in PAS 
In invasive PAS, EVTs can be found beyond the JZ and chorionic villi inside myometrial 
vascular spaces [15,18]. This leads to an absence of the normal plane of cleavage and 
prevents placental separation after delivery. Major haemorrhage occurs when the 
condition has not been diagnosed prenatally and manual placental delivery is 
attempted. Invasion of larger vessels in the outer myometrium as far as the uterine 
serosa in PAS is most certainly determined by access rather than a trophoblastic 
malfunction. Deeper than normal EVT invasion through the entire depth of the 
myometrium transforms the arterial vasculature beyond the JZ [18,19]. In cases of pre-
existing scar defects, EVT cells can infiltrate directly the tissue around the radial and 
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even the arcuate arteries leading to their excessive dilatation [18]. This is the most 
prominent feature of invasive PAS prenatally on ultrasound, and macroscopically on the 
uterine surface at delivery. It is possible these utero-placental vascular changes in the 
accreta area result from both neovascularization and/or increased recruitment of deep 
uterine vessels by EVT and chorionic villi beyond the JZ. 
Although the numbers of interstitial EVT cells are increased in PAS, several 
authors have found that spiral artery remodeling is focally reduced. The deficiency is 
seen more in PAS cases without local decidua [15], and remodeling is sometimes 
completely absent in the accreta area [19]. Even the most invasive forms of PAS 
pregnancies are not associated with a higher incidence of placental-related disorders 
such pre-eclampsia and/or fetal growth restriction. These disorders are due to a 
reduction in trophoblast invasion and failure of conversion of the spiral arteries most of 
which retain their vaso-reactivity beyond 22 weeks of gestation. Pre-eclampsia is 
essentially a disorder affecting primigest women with ethnic variations whereas PAS is 
a disorder of multiparous with no influence of ethnicity. One can hypothesize that in the 
absence of a decidua, the normal release of proteases and cytokines from activated 
maternal immune cells is missing, impairing arterial remodelling. This phenomenon is 
limited to the scar area in PAS and thus unlikely to lead to a systemic disorder such as 
pre-eclampsia. 
 
ULTRASOUND-PATHOLOGIC CORRELATIONS 
Ultrasound imaging and in particular colour-Doppler imaging (CDI) have enabled the 
investigation in vivo of the development of placental circulations in normal and abnormal 
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pregnancies from the first weeks after implantation. There are now more than 1000 
cases reports and case series describing the prenatal diagnosis of PAS at different 
gestational ages, providing a unique insight into the development of accreta placental 
tissue and its interaction with the uterine wall.  However, ultrasound studies of accreta 
placentation have been as heterogeneous as the histopathologic studies, in particular 
regarding the terminology used to describe the different ultrasound signs associated 
with PAS and the lack of detailed histopathologic correlations [14]. In 2016, The 
European Working Group on Abnormally Invasive Placenta (EW-AIP) and the Ad-hoc 
International AIP Expert Group [20] proposed standardized descriptions for reporting the 
ultrasound signs used for the prenatal diagnosis of PAS (Table 2). To facilitate the etio-
pathologic analysis of the ultrasound changes associated with PAS, we have separated 
them according to their uterine or placental origin:  
 
Anomalies of the uterine wall  
After a full-term pregnancy, the myometrium remains thinner and more elastic in 
subsequent pregnancies. If the pregnancy has resulted in a CD, the anterior portion of 
the lower uterine segment will be transformed by the scarring process(es) into an area 
where the residual myometrial tissue is mixed with fibrinous tissue. As a result, the scar 
area is always thinner containing less muscular tissue and thus more prone to 
dehiscence, in particular during the third trimester when the lower segment stretches to 
accommodate the growing fetus. This phenomenon will be influenced by prior multiple 
pregnancies and the number of prior CDs, but also by poor scarring process resulting in 
permanent scar defect with limited endometrial re-epithelialisation [15,18]. Not 
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surprisingly, the ultrasound signs defined as the thinning of the uterine myometrial to 
<1mm and the loss of the subplacental clear zone in the myometrium under the 
placental bed, corresponding to the normal decidua and JZ, have been the most 
common findings in case reports and cohort studies [14]. In isolation, these signs are 
not specific of PAS (Fig. 3) and may be affected by the placental position, the pressure 
of the ultrasound probe, filling of the bladder and the amount of scar tissue in the 
myometrium. 
The hypervascularity of the placental bed was described more recently when CDI 
was used more routinely to evaluate women at high risk of PAS. In women with the 
highest risk of PAS, those with prior multiple CDs and/or presenting with a low-lying or 
placenta praevia, hypervascularity between the myometrium and the utero-vesical 
posterior wall of the bladder has been reported in over 80% of cases complicated by 
PAS [13,14]. CDI is not essential to confirm the diagnosis of PAS in expert hands, but 
may assist in the screening of women at higher risk [13]. As uterine vascularity and 
vascular dilatation increases with advancing parity, increased vascularity under the 
placental bed is not always pathognomonic of PAS (Fig.4 and 5).  
Interruption of the bladder wall with loss of the hyperechoic line between the 
uterine serosa and bladder lumen has been rarely described on ultrasound [14]. This 
sign may result from the villous invasion into the muscle of the posterior wall of the 
bladder in placenta percreta or may represent an ultrasound artefact arising from the 
massive hypervascularity of the placental bed [18]. Similarly, the presence of bridging 
vessels across the myometrium and beyond the uterine serosa into the bladder before 
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disappearing has been reported inconsistently in cases of PAS [14] and may be the 
consequence of an ultrasound artefact [18]. 
 
Anomalies of the placenta 
The presence of intra-placental lacunae causing large and irregular sonolucent areas 
within the placental mass and giving it a “moth eaten” appearance is the most common 
ultrasound sign described in PAS [14]. This anomaly results from the distortion of the 
normal placental cotyledonary anatomy by the unrestricted entry from the beginning of 
the second trimester of high velocity (turbulent) flow from the deep arterial vasculature 
of the myometrium [18]. Not surprisingly, in more that 50% of invasive cases of PAS 
feeder vessels can be seen entering the lacunae [14]. Lacunae must be differentiated 
on ultrasound from placental lakes (Fig. 4 and 5) which are echolucent areas in the 
center of a cotyledon, under the chorionic plate or in the marginal areas and are part of 
the normal anatomical development of the definitive placenta [18]. 
Placental bulge distorting the extra-uterine organs and focal exophytic mass of 
placental tissue extending beyond the serosa have been rarely described in PAS [14] 
and should only been seen in cases of placenta percreta [18].  
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CONCLUSIONS 
The comparison of in vivo ultrasound features with histopathologic findings is essential 
in order to better understand the phenomenon of accreta placentation. As we can only 
witness the consequences of an abnormally deep EVT migration and villous attachment 
below the JZ at delivery, what happens during the initial phase of placentation in PAS 
several months previously remains a mystery. Both ultrasound features and 
histopathologic data support the concept that the morphological changes observed in 
the EVT in PAS are environmental, and the consequence of an unusual and prolonged 
interaction with the highly vascularised deep myometrium which these cells would 
normally not reach in normal placentation. Overall these findings support the concept of 
a primary deciduo-myometrium defect in PAS, exposing the uterine myometrium below 
the JZ to the migrating EVT. The loss of the normal plane of placental cleavage from the 
uterine wall and the excessive vascular remodelling of the radial and arcuate arteries 
can explain the prenatal ultrasound findings and the clinical consequence of accreta 
placentation, in particular in its invasive forms. Neovascularisation or dilation of the 
myometrial vasculature induced by the trophoblast increases the risk of haemorrhage 
when manual removal of an undiagnosed placenta accreta is attempted.   
 
 
TEACHING POINTS 
 The recent increase in placenta accreta spectrum disorders is directly linked to 
the increase incidence in uterine scar from previous surgery, mainly caesarean 
section. 
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 There is mounting evidence that abnormal villous adherence and/or invasion of 
the uterine wall is due to a defect of the junctional zone between the superficial 
myometrium and the endometrium. 
 Macroscopic and microscopic examinations of hysterectomy specimens or 
myometrial samples from an abnormal placentation site remain the gold standard 
of reference to confirm the diagnosis of PAS.  
 Trophoblast biological changes observed with immunohistochemistry in PAS are 
mainly secondary to the development in a different environment with no 
interaction with decidual tissue.  
 Correlations of the ultrasound imaging from early in pregnancy with 
histopathological examination at birth are pivotal to better understand the natural 
evolution of PAS, and are essential to improve the diagnosis and management of 
this increasingly common major obstetric complication.  
 Standardized ultrasound and clinical terminology is essential to allow direct 
correlations between antenatal and delivery findings in PAS and provide more 
accurate population epidemiology data. 
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Table 1: Histopathological and immunostaining changes observed in PAS [15] 
according to anatomical level. 
 
__________________________________________________________________ 
 
VILLOUS TROPHOBLAST  
 
- Lower syncytiotrophoblast immunostaining for MicroRNA-34a, TGF-β, E-CAD, 
EGF c-(erbB-2), VEGFR-2 and RTK Tie-2. 
- Higher syncytiotrophoblast immunostaining for EGFR and TIMP-1. 
 
EXTRAVILLOUS TROPHOBLAST (EVT) 
 
- Increased in the size, numbers and depth of myometrial invasion of EVTs 
- Reduced formation of MNGCs. 
- Higher EVT immunostaining for VEGF and phosphotyrosine. 
- Lower EVT immunostaining for sFLT-1. 
 
UTERO-PLACENTAL VASCULATURE 
 
- Decreased proportion of remodelled spiral arteries.  
- Greater degree of remodelling in radial/arcuate arteries in increta and percreta. 
 
__________________________________________________________________ 
 
E-CAD= E-cadherin; EGFR= epidermal growth factor receptor; MNGCs= multinucleated 
trophoblast giant cells; RTK= receptor tyrosine kinase; RTPCR= reverse transcription 
polymerase chain reaction; sFLT-1= Soluble fms-like tyrosine kinase; TGF-β= 
Transforming growth factor beta; TIMP-1 tissue inhibitors of matrix metalloproteinase; 
VEGF= Vascular endothelial growth factor; VEGFR= Vascular endothelial growth factor 
receptor. 
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Table 2. Ultrasound signs according to gray-scale versus colour-Doppler imaging using 
the standardized descriptions proposed recently by the European Working Group on 
Abnormally Invasive Placenta (EW-AIP) and the AIP international expert group, 
modified from [20].  
 
 
Grey-scale imaging 
- Thinning of the uterine myometrium.  
- Bladder wall interruption between the uterine serosa and bladder lumen.  
- Loss of the subplacental clear zone.  
- Intra-placental lacunae.  
- Extra-uterine placental bulge.  
- Focal placental exophytic mass.  
 
 
Colour-Doppler imaging (CDI)  
- Utero-vesical hypervascularity.  
- Hypervascularity of the placental bed.  
- Bridging vessels beyond the uterine serosa. 
- Lacunae feeder vessels.  
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Figure legends 
Fig 1. A. Transvaginal ultrasound view of the uterus in a non-pregnant woman with a 
history of 2 prior CDs. Note the scar defects through the uterine wall at the junction 
between the cervix and lower uterine (U) segment (arrow). B. Transvaginal ultrasound 
view of pregnant uterus at 7 weeks gestation after 3 prior CDs showing the lower end of 
the placenta (arrow) protruding inside a large caesarean scar defect (CSD). The 
pregnancy was uncomplicated delivered at 36 weeks with the edge of the placenta 
visible under the uterine serosa but with no clinical evidence of placenta percreta. 
 
Fig 2. Microscopic view of the placental bed from a hysterectomy specimen at 34 weeks 
in a pregnancy complicated by placenta previa increta (H&E x 5) showing the disruption 
of the decidua by placental villi (arrow) invading the myometrium. 
 
Fig 3. Transvaginal ultrasound view of the lower segment of the uterus in a non-
pregnant woman with a history of 3 prior CDs presenting with a major placenta (P) 
previa covering partially the cervix. Note the uterine myometrial of <1mm in thickness 
and the loss of the subplacental clear zone between the placental bed and the bladder 
(B) wall (arrow). There was no evidence of PAS at birth. 
 
Fig 4. Transabdominal ultrasound longitudinal views of the placental bed at 22 weeks in 
a pregnancy after 1 prior CD presenting with a major placenta (P) previa covering the 
cervix showing: A. areas of absent myometrium and irregular subplacental clear zone 
and numerous lacunae giving the placenta a “moth eaten” appearance on grey-scale 
imaging; B. increased and anarchic hypervascularity of the placental bed on CDI. An 
extended zone of placenta increta was confirmed at birth. F= fetus. 
 
Fig 5. Transabdominal ultrasound longitudinal views of the placental bed at 28 weeks in 
a pregnancy after 2 prior CDs presenting with a major placenta (P) previa covering 
partially the cervix showing: A. area suggesting a disruption of the uterine wall between 
the placental bed and the bladder (B) with absent myometrium (arrow) and 
intraplacental lakes on grey-scale imaging. B. CDI indicates a normal utero-placental 
circulation. No PAS was found at birth. F= fetus. 
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